Venmax Drugs And Pharmaceuticals Ltd. (VENMA) Share Price Rises 19.11% Today

Venmax Drugs And Pharmaceuticals Ltd. Share Price rises 19.11% today, reaching Rs 19.2 with a market cap of Rs 18.67 crore.

Venmax Drugs And Pharmaceuticals Ltd. Share Price has experienced a significant rise today, closing at Rs 19.2, marking a 19.11% increase from its previous close of Rs 16.12. This notable price movement elevates the company's market capitalisation to Rs 18.67 crore, placing it firmly within the Micro Cap category. The stock's impressive gain today has surpassed the qualifying threshold of 8.1% set for its market-cap category, making it a top gainer in the market.

The surge in Venmax's share price today is noteworthy, especially given the absence of a clear company-specific catalyst in the supplied data. Investors and analysts alike are closely monitoring this development, as the stock's performance today could indicate potential market interest or speculative trading activity. The Pharmaceuticals & Drugs industry, to which Venmax belongs, is known for its volatility, and today's price action may reflect broader sector trends or investor sentiment.

Venmax Drugs And Pharmaceuticals Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 19.2
Previous Close	Rs 16.12
Today's Change	+Rs 3.08 (+19.11%)
Day Open	Rs 16.5
Day High	Rs 19.3
Day Low	Rs 15.85
Current Volume (BSE)	12,897
BSE Traded Volume	12,897
Combined NSE + BSE Volume	12,897
Turnover	Rs 0.02 crore
Market Capitalisation	Rs 18.67 crore
Market Cap Category	Micro Cap
Qualifying Threshold Cleared	8.1%

Today's trading session saw Venmax Drugs And Pharmaceuticals Ltd. open at Rs 16.5, reaching a high of Rs 19.3 and a low of Rs 15.85, before closing at Rs 19.2. The stock's turnover for the day was Rs 0.02 crore, with a total volume of 12,897 shares traded on the BSE. This volume is indicative of active trading interest, although it remains relatively modest in absolute terms.

Venmax's share price rise today is significant, as it cleared the qualifying threshold of 8.1% for the Micro Cap category. This threshold is a benchmark for identifying notable price movements within smaller market capitalisation stocks. The stock's 19.11% gain today is well above this threshold, highlighting its status as a top gainer in the market.

The price action today suggests that Venmax's shares are attracting attention, possibly due to speculative trading or broader market trends affecting the Pharmaceuticals & Drugs sector. While the exact reasons for today's rally remain unclear, the stock's performance is likely to draw interest from both retail and institutional investors looking for potential opportunities in the market.

Venmax Drugs And Pharmaceuticals Ltd. Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 18.67 crore
P/E Ratio	75.59x
P/B Ratio	1.32x
ROE	0%
ROCE	0%
EPS	Rs 0.21
Dividend Yield	0%

Venmax Drugs And Pharmaceuticals Ltd. was valued at a P/E ratio of 75.59x, a P/B ratio of 1.32x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 0% and ROCE of 0%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 0.21, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Venmax Drugs And Pharmaceuticals Ltd. has a market capitalisation of Rs 18.67 crore, placing it in the Micro Cap category. The company's P/E ratio is 75.59, which is considerably higher than the industry median of 26.62 and the average of 78.1. This suggests that the stock may be perceived as expensive relative to its earnings, especially when compared to its peers in the Pharmaceuticals & Drugs industry.

The company's P/B ratio stands at 1.32, which is below the industry median of 1.84 and the average of 2.49. This indicates that Venmax may be valued more conservatively in terms of its book value compared to its industry peers.

Venmax's ROE and ROCE are both reported as 0, which may raise concerns about the company's ability to generate returns on equity and capital employed. Additionally, the company's EPS is Rs 0.21, reflecting the earnings attributable to each share. The absence of a dividend yield suggests that the company may not be distributing profits to shareholders in the form of dividends at this time.

Overall, the fundamental analysis indicates that while Venmax is trading at a high P/E ratio, its P/B ratio suggests a more conservative valuation in terms of book value. Investors should consider these factors alongside the company's growth prospects and industry trends when evaluating the stock.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Companies in Benchmark	138
Company P/E Ratio	75.59x
Benchmark Median P/E	26.62x
Benchmark Average P/E	78.1x
Benchmark P/E Range	3.65x to 3,482.29x
Companies with P/E Data	103
Company P/B Ratio	1.32x
Benchmark Median P/B	1.84x
Company ROE	0%
Benchmark Median ROE	9.93%
Company ROCE	0%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 18.67 crore
Benchmark Median Market Cap	Rs 151.5 crore

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs. The numerical benchmark uses 138 same industry companies from the supplied master-data set.

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a P/E ratio of 75.59x, which is above the benchmark median of 26.62x, a difference of +183.96%. The benchmark contains 103 companies with P/E data, ranging from 3.65x to 3,482.29x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a ROE of 0%, which is below the benchmark median of 9.93%, a difference of -100%. Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a ROCE of 0%, which is below the benchmark median of 12.97%, a difference of -100%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Venmax Drugs And Pharmaceuticals Ltd. operates within the Healthcare sector, specifically in the Pharmaceuticals & Drugs industry. The industry comprises 138 companies, providing a broad benchmark for comparison. Venmax's P/E ratio of 75.59 is significantly higher than the industry median of 26.62, indicating a premium valuation relative to its peers. However, it is close to the industry average of 78.1, suggesting that high valuations are not uncommon in this sector.

The company's P/B ratio of 1.32 is below the industry median of 1.84 and the average of 2.49, indicating a more conservative valuation in terms of book value. The industry benchmark also shows a wide range of P/B values, from a minimum of -16.61 to a maximum of 17.25, highlighting the diversity in valuations within the sector.

Venmax's ROE and ROCE are both reported as 0, which is below the industry medians of 9.93 and 12.97, respectively. This suggests that the company may face challenges in generating returns compared to its peers. The Healthcare sector, particularly the Pharmaceuticals & Drugs industry, is known for its dynamic nature, with companies often experiencing fluctuations in performance due to regulatory changes, market demand, and innovation.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Morepen Laboratories Ltd.	MOREPENLAB	2,947.44	32.68	2.49	29.2	27.13
Dishman Carbogen Amcis Ltd.	DCAL	2,885.59	29.98	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,881.37	41.8	8.51	28.21	26.35
Panacea Biotec Ltd.	PANACEABIO	2,699.01	0	3.18	0	5.36
Hikal Ltd.	HIKAL	2,678.09	0	2.28	15.22	16.15

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a P/E ratio of 75.59x compared with the displayed peer median of 29.98x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 0% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a market capitalisation of Rs 18.67 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

When comparing Venmax Drugs And Pharmaceuticals Ltd. to its peers, several key differences emerge. Morepen Laboratories Ltd. (MOREPENLAB) has a P/E ratio of 32.68, significantly lower than Venmax's 75.59, indicating a more attractive valuation in terms of earnings. Morepen also boasts a high ROE of 29.2% and ROCE of 27.13%, reflecting strong profitability and capital efficiency.

Dishman Carbogen Amcis Ltd. (DCAL) presents a P/E ratio of 29.98 and a P/B ratio of 0.44, suggesting a lower valuation compared to Venmax. However, its negative ROE and ROCE indicate challenges in profitability and capital management.

Kwality Pharmaceuticals Ltd. (KPL) offers a P/E ratio of 41.8 and a P/B ratio of 8.51, with strong ROE and ROCE figures of 28.21% and 26.35%, respectively. This positions Kwality as a robust competitor in terms of profitability and valuation.

Overall, Venmax's higher P/E ratio suggests a premium valuation, while its zero ROE and ROCE highlight potential areas for improvement compared to its peers.

Why Investors Are Watching Venmax Drugs And Pharmaceuticals Ltd.

Investors are closely monitoring Venmax Drugs And Pharmaceuticals Ltd. due to its significant price rise today and its position within the dynamic Pharmaceuticals & Drugs industry.

• Price Action: The stock rose 19.11% today, surpassing the Micro Cap threshold.
• Technical Position: RSI indicates neutral momentum, suggesting balanced trading conditions.
• Fundamental Context: High P/E ratio and zero ROE/ROCE highlight valuation and profitability considerations.
• Sector Positioning: Operates in a volatile industry with diverse valuation metrics.

Investors should continue to monitor Venmax's share price movements, technical indicators, and industry trends to assess potential opportunities and risks associated with the stock.

About Venmax Drugs And Pharmaceuticals Ltd.

Venmax Drugs And Pharmaceuticals Ltd. is a company operating in the Pharmaceuticals & Drugs industry, part of the broader Healthcare sector. The company engages in the development, manufacturing, and distribution of pharmaceutical products. Its operations are focused on providing a range of drugs and healthcare solutions to meet the needs of patients and healthcare providers.

As a player in the Pharmaceuticals & Drugs industry, Venmax is exposed to the dynamic nature of the sector, which includes regulatory changes, market demand shifts, and innovation-driven growth. The company's market capitalisation of Rs 18.67 crore places it in the Micro Cap category, highlighting its position as a smaller player in the industry.

Venmax's business model revolves around leveraging its expertise in pharmaceuticals to deliver quality products while navigating the challenges and opportunities presented by the healthcare landscape.

Track Venmax Drugs And Pharmaceuticals Ltd. Share Price on Univest

Use Venmax Drugs And Pharmaceuticals Ltd. (VENMA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors and market enthusiasts can track the live share price of Venmax Drugs And Pharmaceuticals Ltd. on Univest. The platform provides access to technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights. By staying informed through Univest, users can make more educated decisions regarding their investments in the stock market.

Frequently Asked Questions

What is the current share price of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. The current share price of Venmax Drugs And Pharmaceuticals Ltd. is Rs 19.2, reflecting a 19.11% increase from the previous close of Rs 16.12. The stock moved 19.11% during the session.

How much did Venmax Drugs And Pharmaceuticals Ltd. share price rise today?

Ans. Venmax Drugs And Pharmaceuticals Ltd. share price rose by 19.11% today, closing at Rs 19.2, a significant gain from its previous close. The stock moved 19.11% during the session. The intraday range extended from Rs 15.85 to Rs 19.3.

What is the market capitalisation of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. The market capitalisation of Venmax Drugs And Pharmaceuticals Ltd. is Rs 18.67 crore, categorising it as a Micro Cap company. The company operates in the Healthcare sector. Its P/E ratio is 75.59x.

What is the P/E ratio of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. The P/E ratio of Venmax Drugs And Pharmaceuticals Ltd. is 75.59, which is higher than the industry median of 26.62. The company trades at a P/E ratio of 75.59x. Its P/B ratio is 1.32x.

How does Venmax Drugs And Pharmaceuticals Ltd. compare to its peers?

Ans. Venmax Drugs And Pharmaceuticals Ltd. has a higher P/E ratio compared to peers like Morepen Laboratories Ltd., indicating a premium valuation. Comparable listed companies include Morepen Laboratories Ltd., Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd.

What sector does Venmax Drugs And Pharmaceuticals Ltd. operate in?

Ans. Venmax Drugs And Pharmaceuticals Ltd. operates in the Healthcare sector, specifically within the Pharmaceuticals & Drugs industry. The stock belongs to the Healthcare sector. Its industry classification is Pharmaceuticals & Drugs.

What are the ROE and ROCE of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. Both the ROE and ROCE of Venmax Drugs And Pharmaceuticals Ltd. are reported as 0, indicating no returns on equity or capital employed. ROE stands at 0%. ROCE stands at 0%.